Boehringer Ingelheim marks COP26 by announcing updates to its strategic approach to sustainable development…
Tag:
Boehringer Ingelheim
-
-
Lifestyle & Healthslider
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
by Karine Ayoubby Karine Ayoub• Boehringer Ingelheim marks the World Health Summit 2021 by announcing updates to its…
-
Lifestyle & Healthslider
Landmark trial, EMPEROR-Preserved, demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
by Karine Ayoubby Karine AyoubIn this clinical study for adults with heart failure with preserved ejection fraction, empagliflozin…
-
Lifestyle & Healthslider
Leading Healthcare Experts Highlight Importance of Multidisciplinary Treatment Approach at ‘2021 Regional Interchange on Diabetes’
by Karine Ayoubby Karine AyoubOver 300 nephrologists, endocrinologists, internists, diabetologists and cardiologists from across the Middle East and…
-
Lifestyle & Healthslider
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
by Karine Ayoubby Karine AyoubStrong R&D commitment to developing therapeutics against SARS-CoV-2 virus Overall R&D investment up 7%…
-
slider
Boehringer Ingelheim Recognized As Global Top Employer for 2021
by Karine Ayoubby Karine AyoubBoehringer Ingelheim has been recognized as one of the 16 Top Employers Worldwide by…
-
Lifestyle & Health
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart…
-
Pharmaceuticalslider
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
Sixty million people across the Middle East may be at risk of developing respiratory…
-
Lifestyle & Health
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim‘s Global Support Program aiming at bringing more financial relief to the countries…
-
Sharp increase in net sales to nearly 18.1 billion euros (+15.7 per cent…